Media
Jiaxing Municipal Party Committee Secretary Chen Wei Visits Angel Pharmaceuticals for Inspection and Guidance
On the afternoon of October 10, Chen Wei, Secretary of the Jiaxing Municipal Party Committee, visited Angel Pharmaceuticals for inspection and guidance. He was accompanied by city leaders Ni Huping and Xu Yong, as well as district leaders Shao Panfeng and Chen Guangzhen. Angel Pharmaceuticals is currently dedicated to the R&D of innovative drugs for oncology and autoimmune diseases. Secretary Chen Wei and his delegation toured the Jiaxing headquarters of Angel Pharmaceuticals and listened to a presentation by Dr. Li Kecheng, Vice President of the company, on the company's innovative drug R&D processes and progress.
During the visit to the R&D center, key members of the company, including Dr. Chen Haiyan, Vice President; Mr. Guo Yong, Senior Vice President of Clinical Development; Dr. Xu Qijin, Senior Director of Biology; and Dr. Liao Jianchun, Senior Director of Medicinal Chemistry, reported on the construction and development of the company's chemical process development, medicinal chemistry, bioanalysis, and pharmaceutical formulation laboratories.
When Secretary Chen Wei learned that the company is fully advancing the development of its proprietary pipeline and proprietary technology platforms, with some projects having successfully entered the clinical development stage, he expressed his full recognition and encouraged the company to continue making significant strides forward and strive to achieve industrialization as soon as possible. Secretary Chen Wei expressed his hope that Angel Pharmaceuticals, leveraging its strength in intellectual capital, will deepen its expertise in the professional field, adhere to innovation-driven development, intensify R&D efforts, and develop more affordable and high-quality medicines to better safeguard the life and health of the people.
About Angel Pharmaceuticals
Angel Pharmaceuticals is an innovative drug company dedicated to oncology and autoimmune diseases. With the mission of benefiting Chinese patients, Angel is committed to bringing globally top-tier innovative drugs for serious diseases such as cancer and autoimmune disorders to China. In October 2020, Angel Pharmaceuticals completed its Series A financing round, co-invested by Beta Fund, Hisun Pharmaceuticals, Tigermed, and Puhua Investment, and established a strategic partnership with Corvus Pharmaceuticals (CRVS) of the U.S. For more information, please visit www.angelpharma.com.
